J Korean Ophthalmol Soc > Volume 57(12); 2016 > Article
Journal of the Korean Ophthalmological Society 2016;57(12):1897-1902.
DOI: https://doi.org/10.3341/jkos.2016.57.12.1897    Published online December 15, 2016.
Combination Therapy with Photodynamic Therapy and Intravitreal Bevacizumab in Idiopathic Macular Telangiectasia Type I.
In Geun Kim, Ji Eun Lee, Jung Min Park
1Department of Ophthalmology, Maryknoll Medical Center, Busan, Korea. pjm1438@hanmail.net
2Department of Ophthalmology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
광역학치료와 베바시주맙을 이용한 특발 중심와부근 모세혈관확장증 I형의 치료
메리놀병원 안과1, 부산대학교 의학전문대학원 부산대학교병원 안과학교실2
We investigated the clinical manifestations of combination therapy with photodynamic therapy (PDT) and intravitreal bevacizumab in idiopathic macular telangiectasia type I patients. METHODS: The present study included 7 patients who visited our clinic from May 2008 to February 2011 complaining of decreasing visual acuity and diagnosed as idiopathic macular telangiectasia type I including visible aneurysms at juxtafoveal area and telangiectatic vessels leakage based on fluorescein angiography. Additionally, all patients were treated with combination therapy with PDT and intravitreal bevacizumab. RESULTS: Visual acuity improved from 0.48 ± 0.14 (log MAR) to 0.18 ± 0.17 (log MAR) after the combination therapy, however, there was no change in intraocular pressure between before (17.9 ± 3.1) and after (16.8 ± 2.3) therapy. After combination therapy, fluorescein angiography showed decreased leakage of telangiectatic vessels and optical coherence tomography showed only minimal intraretinal edema. Central subfield macular thickness decreased from 301.9 ± 50.7 μm to 193.6 ± 58.8 μm after the combination therapy. CONCLUSIONS: Combination therapy with intravitreal bevacizumab injection and PDT in patients with idiopathic macular telangiectasia type I can result in a rapid decrease of macular edema, which can lead to rapid visual recovery.
Key Words: Idiopathic macular telangiectasia type I;Intravitreal bevacizumab;Photodynamic therapy

Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2022 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next